75%Confidence
0Views
FDASource
2026-04-11Date
Summary
Amerisource Health Services recalls Meclizine tablets due to failed specifications, indicating potential efficacy or safety issues in a common anti-nausea drug. This could disrupt distribution and lead to inventory write-offs, affecting Amerisource's logistics revenue.
Actionable: Check Amerisource's recall management processes and ensure alternative Meclizine suppliers are available.
AI Confidence: 75%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Dis
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now